Kura Oncology (KURA) Change in Receivables (2025 - 2026)

Kura Oncology's (KURA) quarterly Change in Receivables came in at $544000.0 in Q1 2026, down 98.83% year-on-year from $46.7 million in Q1 2025, and up 102.01% on a QoQ basis from -$27.1 million in Q4 2025.

Kura Oncology (KURA) Change in Receivables (2025 - 2026) Analysis & Trends

Kura Oncology (KURA) has 2 years of Change in Receivables data on file, last reported at $544000.0 in Q1 2026.

  • On a quarterly basis, Change in Receivables fell 98.83% year-over-year to $544000.0 in Q1 2026; TTM through Mar 2026 was -$39.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.7 million, up 227.38% from the prior year.
  • Change in Receivables for Q1 2026 stood at $544000.0, up from -$27.1 million in the prior quarter.
  • Over the last five years, Change in Receivables for KURA reached as high as $46.7 million in Q1 2025 and fell as low as -$44.2 million in Q2 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 75.30 Mn
4 NuCana 279.75 Bn 279.75 Bn - 2.84 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -39.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -1.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Kura Oncology 925.97 Mn 925.97 Mn 18.00 Mn 544,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 544,000.00
Mar 31, 2026 544,000.00
Dec 31, 2025 -27.13 Mn
Dec 31, 2025 -27.13 Mn
Sep 30, 2025 31.36 Mn
Sep 30, 2025 31.36 Mn
Jun 30, 2025 -44.17 Mn
Jun 30, 2025 -44.17 Mn
Mar 31, 2025 46.69 Mn
Mar 31, 2025 46.69 Mn